Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699227 | 0.84 | NOS3 (0.38) | NPC1RAB9AL3MBTL1HTTKDM4E | |
| SCHEMBL13699045 | 0.80 | NOS3 (0.40) | NPC1RAB9AL3MBTL1HTTKDM4E | |
| SCHEMBL13699043 | 0.76 | NPC1 (0.47) | NPC1RAB9AL3MBTL1HTTKDM4E | |
| SCHEMBL14149889 | 0.75 | NOS2 (0.44) | NPC1RAB9AL3MBTL1HTTKDM4E | |
| SCHEMBL14292504 | 0.75 | NOS2 (0.44) | NPC1RAB9AL3MBTL1HTTKDM4E | |
| SCHEMBL13699051 | 0.74 | ALDH1A1 (0.39) | AMY1ANOS3NOS1NOS2NAPRT | |
| SCHEMBL24061463 | 0.72 | TLR8 (0.51) | NPC1RAB9AL3MBTL1HTTKDM4E | |
| SCHEMBL13699039 | 0.71 | CHRNB2 (0.55) | NPC1RAB9AKDM4EMAPT | |
| SCHEMBL21953775 | 0.69 | NOS3 (0.41) | NPC1RAB9AL3MBTL1HTTKDM4E | |
| SCHEMBL10072090 | 0.69 | NOS3 (0.48) | NPC1RAB9AL3MBTL1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | NPC1 53/4885RAB9A 1907/4885L3MBTL1 2779/4885 |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ABCB11, ABCB1, CYP2B6 | NPC1 91/4885RAB9A 3390/4885L3MBTL1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.